Azeliragon is an orally bioavailable inhibitor of the receptor for advanced glycation endproducts (RAGE) with Kd of 12.7 nM for human recombinant sRAGE. While RAGE transports amyloid-β (Aβ) from plasma into the CNS, Azeliragon is evaluated as a potential treatment for patients with mild-to-moderate Alzheimer's disease (AD).

RAGE antagonist